Mr T

[Mr T @MrTprh]

@TheCryptoMaze Agree. Very dumb decision

[Mr T @MrTprh]

$PTN Abandons their drug pl7737 for a 2nd gen candidate. Pushing their timeline back to H1 2027. Thoughts?

[Mr T @MrTprh]

@homoinsularis20 @BPharmCatalyst It’s not correct.

[Mr T @MrTprh]

$PTN

[Mr T @MrTprh]

@B_trader__ Yes. Waiting for a breakout.

[Mr T @MrTprh]

@singhlosophy 200$/share before dilution?

[Mr T @MrTprh]

@seedy19tron Why close $ptn right before the ind?

[Mr T @MrTprh]

$ptn has a market cap of ~$150m fd compared to rhytms ~$7,4b. $ptn has a huge upside and they will definitely take a big size of that $5-7b market share with their new oral asset pl7737.

[singhlosophy @singhlosophy]

For context, $PTN at $100 is only a $200 million market cap.
Hypothalamic Obesity is projected to be a $5-7 billion market space by 2033. $RYTM won't be taking 100% of that market share.
Worth owning both for this target indication.
https://t.co/EguBQpmLxH

[Mr T @MrTprh]

@singhlosophy Bunch of puss*es

[Mr T @MrTprh]

@seedy19tron What’s your take on Palatins asset pl8177? P2 poc data in UC. Safe oral therapy, a non-immunosuppressive alternative, first-in-class mechanism of action. Will they outlicense it and to whom?

[Mr T @MrTprh]

https://t.co/GxsrCgsSbC
Pt: 60$
$ptn

[Mr T @MrTprh]

@singhlosophy Point72 aswell ✌️

[Mr T @MrTprh]

$PTN

https://t.co/y3Y7kd4JPm

TP: 53$

[Mr T @MrTprh]

@seedy19tron $ptn may be one of the most asymmetric risk/reward opportunities in the entire small-cap biotech space right now.

[Mr T @MrTprh]

@PalatinTech 👏👍

[Mr T @MrTprh]

@BAMBossie81 Reverse split to get relisted on NYSE incoming